Abiopharma

🔍 Douglass Brian Robb (Executive)

Company: REPLIGEN CORP (RGEN)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 2,288 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: false | shares_owned_after: 8,540.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,143 shares of Stock Option (Right to Buy) at $163.86 per share (Derivative)
  Date: 2025-12-31 | Code: A | Expires: 2035-12-31 | equity_swap_involved: false | shares_owned_after: 2,143.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Mr. Douglass was awarded 2,288 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in substantially equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock.
• F2: The shares will vest in substantially equal installments over a three-year period with each such vesting date occurring on the anniversary of the grant date.